Analysed SCYNEXIS INC (SCYX:NASDAQ) News Sources
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease
31-03-2026
yahoo.com
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
31-03-2026
yahoo.com
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy
12-03-2026
yahoo.com
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
04-03-2026
yahoo.com
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
26-02-2026
yahoo.com
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
17-02-2026
yahoo.com
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
28-01-2026
yahoo.com
What is the current price of SCYNEXIS INC (SCYX:NASDAQ)?
The current price of SCYNEXIS INC (SCYX:NASDAQ) is $1.01.
SCYNEXIS INC (SCYX:NASDAQ) absolute price change since previous trading day?
The absolute price change of SCYNEXIS INC (SCYX:NASDAQ) since the previous trading day is $0.01.
SCYNEXIS INC (SCYX:NASDAQ) percentage price change since previous trading day?
The percentage price change of SCYNEXIS INC (SCYX:NASDAQ) since the previous trading day is 1%.
What is the most recent average sentiment score for SCYNEXIS INC (SCYX:NASDAQ)?
The most recent average sentiment score for SCYNEXIS INC (SCYX:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for SCYNEXIS INC (SCYX:NASDAQ)?
The most recent sentiment for SCYNEXIS INC (SCYX:NASDAQ) is .
SEC-8K** Filing Available For SCYNEXIS INC (SCYX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.